Recombinant adeno-associated virus serotype 9 transfection of atherosclerosis mice: determination of the optimal expression time in vivo

doi:10.3969/j.issn.2095-4344.2015.05.014

Abstract

Abstract:

BACKGROUND: Recombinant adeno-associated virus serotype 9 has a high affinity in myocardial tissue, and the expression of recombinant adeno-associated virus serotype 9-enhanced green fluorescent protein (rAAV9-eGFP) in the aorta of atherosclerosis mice is not clear.
OBJECTIVE: To explore the optimal time point of rAAV9-eGFP expression in the aorta of atherosclerosis mice.
METHODS: Atherosclerosis model was established with high-fat diet in 30 ApoE^-/- mice for 16 weeks. Among them, 25 mice were injected with 5.0×10¹¹ vg (virus genomes) rAAV9-eGFP through the tail vein, while the remaining 5 mice were injected with saline, serving as the control group. The virus-transfected mice were killed at 14, 21, 28, 35 and 60 days after transfection, and aortic tissue was harvested. The expression of enhanced green fluorescent protein was detected with laser scanning confocal microscope. Western blot assays were used to detect the expression of enhanced green fluorescent protein in aorta. The expression of enhanced green fluorescent protein in vivo was observed and the optimal expression time point was determined.
RESULTS AND CONCLUSION: rAAV9-eGFP effectively transfected the aorta of atherosclerosis mice, enhanced green fluorescent protein was expressed in aortic tissue, and the expression intensity increased gradually with the increasing transfection time. The highest expression level was found at 35 days after transfection and then maintained stable at 60 days. There were significant differences at different time points after transfection (P < 0.001). These data indicate that rAAV9-eGFP can be effectively expressed in the aorta of atherosclerosis ApoE^-/- mice and rAAV9-eGFP can be regarded as the optimal vector in the treatment of atherosclerosis.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: Viruses, Enhanced Green Fluorescent Protein, Models, Animal, Atherosclerosis

CLC Number:

R318

Xie Jia, Yang Yi-ning, Ma Yi-tong, Li Xiao-mei, Chen Bang-dang, Liu Fen, Chen Qing-jie, Zhai Hui. Recombinant adeno-associated virus serotype 9 transfection of atherosclerosis mice: determination of the optimal expression time in vivo[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(5): 733-738.

Figures/Tables 4

References

[1] Králová A, Králová Lesná I, Poledne R. Immunological aspects of atherosclerosis. Physiol Res. 2014;63 Suppl 3:S335-342.
[2] Salisbury D, Bronas U. Inflammation and immune system contribution to the etiology of atherosclerosis: mechanisms and methods of assessment. Nurs Res. 2014;63(5):375-385.
[3] Lu X, Kakkar V. Inflammasome and atherogenesis. Curr Pharm Des. 2014;20(1):108-124.
[4] Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Atherosclerosis as an inflammatory disease. Curr Pharm Des. 2012;18(28):4266-4288.
[5] Liu Z, Zhao Y, Wei F, et al. Treatment with telmisartan/ rosuvastatin combination has a beneficial synergistic effect on ameliorating Th17/Treg functional imbalance in hypertensive patients with carotid atherosclerosis. Atherosclerosis. 2014; 233(1):291-299.
[6] Artom N, Montecucco F, Dallegri F, et al. Carotid atherosclerotic plaque stenosis: the stabilizing role of statins. Eur J Clin Invest. 2014;44(11):1122-1134.
[7] Lehrke M, Lebherz C. AAV-mediated gene therapy for atherosclerosis. Curr Atheroscler Rep. 2014;16(9):434.
[8] Skubis-Zegad?o J, Stachurska A, Ma?ecki M. Vectrology of adeno-associated viruses (AAV). Med Wieku Rozwoj. 2013; 17(3):202-206.
[9] Drouin LM, Agbandje-McKenna M. Adeno-associated virus structural biology as a tool in vector development. Future Virol. 2013;8(12):1183-1199.
[10] Tseng YS, Agbandje-McKenna M. Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors. Front Immunol. 2014;5:9.
[11] Werfel S, Jungmann A, Lehmann L, et al. Rapid and highly efficient inducible cardiac gene knockout in adult mice using AAV-mediated expression of Cre recombinase. Cardiovasc Res. 2014;104(1):15-23.
[12] Sun L, Hao Y, Nie X, et al. Construction of PR39 recombinant AAV under control of the HRE promoter and the effect of recombinant AAV on gene therapy of ischemic heart disease. Exp Ther Med. 2012;4(5):811-814.
[13] Park CS, Cha H, Kwon EJ, et al. AAV-mediated knock-down of HRC exacerbates transverse aorta constriction-induced heart failure. PLoS One. 2012;7(8):e43282.
[14] Yang YN, Ji WN, Ma YT, et al. Activation of the ERK1/2 pathway by the CaMEK gene via adeno-associated virus serotype 9 in cardiomyocytes. Genet Mol Res. 2012;11(4): 4672-4681.
[15] Kotchey NM, Adachi K, Zahid M, et al. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol Ther. 2011;19(6):1079-1089.
[16] Miyagi N, Rao VP, Ricci D, et al. Efficient and durable gene transfer to transplanted heart using adeno-associated virus 9 vector. J Heart Lung Transplant. 2008;27(5):554-560.
[17] Kotchey NM, Adachi K, Zahid M, et al. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol Ther. 2011;19(6):1079-1089.
[18] Inagaki K, Fuess S, Storm TA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther. 2006;14(1):45-53.
[19] Daugherty A. Mouse models of atherosclerosis. Am J Med Sci. 2002;323(1):3-10.
[20] 刘剑刚,董国菊,史大卓,等.载脂蛋白E基因敲除小鼠不同周龄动脉粥样硬化的病理变化[J].中国动脉硬化杂志,2005,13(6): 689-692.
[21] Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A. 1984;81(20):6466-6470.
[22] Chu D, Sullivan CC, Weitzman MD, et al. Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors. J Thorac Cardiovasc Surg. 2003;126(3):671-679.
[23] Pacak CA, Mah CS, Thattaliyath BD, et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res. 2006;99(4):e3-9.
[24] Schinkel S, Bauer R, Bekeredjian R, et al. Long-term preservation of cardiac structure and function after adeno-associated virus serotype 9-mediated microdystrophin gene transfer in mdx mice. Hum Gene Ther. 2012;23(6): 566-575.
[25] Piras BA, O'Connor DM, French BA. Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver. PLoS One. 2013;8(9):e75894.
[26] Chaanine AH, Nonnenmacher M, Kohlbrenner E, et al. Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure. Gene Ther. 2014;21(4):379-386.
[27] 向阳,马依彤,杨毅宁,等.重组9型腺相关病毒载体转染小鼠心脏及对心功能的影响[J].中华微生物学和免疫学杂志,2009,29(10): 899-902.
[28] 高霞,马依彤,杨毅宁,等.9型重组腺相关病毒转染体外培养大鼠心肌细胞的影响[J].细胞与分子免疫学杂志,2010,26(01):18-20.
[29] 杜雷,马依彤,杨毅宁,等.9型重组腺相关病毒转染大鼠心脏成纤维细胞的体外研究[J].心血管康复医学杂志,2010,19(2): 121-125.
[30] Baker AH, Kritz A, Work LM, et al. Cell-selective viral gene delivery vectors for the vasculature. Exp Physiol. 2005;90(1): 27-31.
[31] Bostick B, Ghosh A, Yue Y, et al. Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther. 2007;14(22):1605-1609.
[32] Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71(2):343-353.
[33] Irie D, Kawahito H1, Wakana N1, et al. Transplantation of periaortic adipose tissue from angiotensin receptor blocker-treated mice markedly ameliorates atherosclerosis development in apoE-/- mice. J Renin Angiotensin Aldosterone Syst. 2014. in press.
[34] Zhang SH, Reddick RL, Piedrahita JA, et al. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258(5081):468-471.
[35] 康爱君,田枫,张阔,等. 载脂蛋白E基因缺陷(C57BL/6J-ApoE)小鼠血脂及病理组织学观察[J].中国比较医学杂志,2006,16(2): 85-88.
[36] 程军,李金平,田卓,等.ApoE基因敲除小鼠和C57BL/6J小鼠血脂及主动脉组织病理学的对比观察[J].实验动物科学,2008,25(2): 4-6.
[37] 周军,周丽,曾庆仁.高脂饮食诱导APOE和LDLR基因敲除鼠AS斑块形成的分子病理学特征[J].中国现代医学杂志,2009, 19(10): 1460-1464.
[38] Kampschulte M, Stöckl C, Langheinrich AC, et al. Western diet in ApoE-LDLR double-deficient mouse model of atherosclerosis leads to hepatic steatosis, fibrosis, and tumorigenesis. Lab Invest. 2014;94(11):1273-1282.
[39] Prendergast C, Quayle J1, Burdyga T1, et al. Atherosclerosis differentially affects calcium signalling in endothelial cells from aortic arch and thoracic aorta in Apolipoprotein E knockout mice. Physiol Rep. 2014;2(10). pii: e12171.
[40] Kus K, Wisniewska A, Toton-Zuranska J, et al. Significant deterioration of anti-atherogenic efficacy of nebivolol in a double (apolipoprotein E and endothelial nitric oxide synthase) knockout mouse model of atherosclerosis in comparison to single (apolipoprotein E) knockout model. J Physiol Pharmacol. 2014;65(6):877-881.
[41] Getz GS, Reardon CA. Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(5):1104-1115.
[42] 刘春喜,李大庆,王荣,等.血管组织自发荧光的去除方法及应用[J].中华病理学杂志,2008,37(4):276-277.